IRVINE, Calif., July 31, 2019 /PRNewswire/ -- HCP, Inc.
(NYSE: HCP) today announced results for the second quarter
ended June 30, 2019. For the quarter, HCP generated a net loss
of $0.03 per share, NAREIT FFO of
$0.41 per share, FFO as adjusted of
$0.44 per share and blended Total
Portfolio SPP Cash NOI growth of 3.5%.
SECOND QUARTER 2019 FINANCIAL PERFORMANCE AND RECENT
HIGHLIGHTS
– Closed on $842
million of acquisitions in the second quarter, including
$803 million previously announced
- $245 million previously announced
acquisition of Sierra Point Towers in South San Francisco
- $445 million previously announced
acquisition of nine recently-built senior housing properties
operated by Discovery Senior Living ("Discovery")
- $113 million previously announced
acquisition of three recently-built senior housing properties
operated by Oakmont Senior Living ("Oakmont")
- $24 million of other
miscellaneous senior housing acquisitions
- $15 million acquisition of an
on-campus medical office building in Overland Park, Kansas (Kansas City MSA)
– Closed on $528
million of newly announced acquisitions in July 2019
- $228 million four-building life
science campus in Lexington,
Massachusetts
- $284 million portfolio of five
recently-built senior housing properties in California operated by Oakmont
- $16 million building on an
existing HCP life science campus in the Sorrento Mesa submarket of
San Diego, California
– Entered into an agreement to sell our
direct financing lease interests in 13 non-core senior housing
properties for $274 million
– Delivered Phase III of The Cove in
South San Francisco, representing
324,000 square feet of Class A life science space that is 100%
leased
– Added one on-campus medical office
development with a total estimated spend of $12 million to our development program with HCA
Healthcare ("HCA")
– Renewed the senior housing master
lease with Aegis Living ("Aegis") whereby the existing rent will
escalate at 3% per year through 2030
– Amended our lease agreements with
Harbor Retirement Associates ("HRA") to create an 8-property master
lease maturing in 2028
– Completed the previously announced
conversion of an additional 15 senior housing properties operated
by Sunrise Senior Living ("Sunrise") from triple-net leases to
RIDEA structures
– Issued $1.3
billion of senior unsecured notes
– Upsized revolving credit facility to
$2.5 billion and originated a
$250 million unsecured term loan
facility
– Sold 15.7 million shares of common
stock under our ATM equity offering program for estimated net
proceeds of $496 million
– Increased 2019 FFO as adjusted per
share guidance by two cents at the
midpoint and 2019 blended Total Portfolio SPP Cash NOI guidance by
50 basis points at the midpoint
– Named to Corporate Responsibility
Magazine's 100 Best Corporate Citizens List for 2019 and became a
constituent in the Dow Jones Global 1200 ESG Index for the first
time in 2019
SECOND QUARTER COMPARISON
|
Three Months
Ended
June 30, 2019
|
|
Three Months
Ended
June 30, 2018
|
(in thousands, except per share amounts)
|
Amount
|
|
Per Share
|
|
Amount
|
|
Per Share
|
Net income (loss),
diluted
|
$
|
(13,991)
|
|
|
$
|
(0.03)
|
|
|
$
|
89,481
|
|
|
$
|
0.19
|
|
NAREIT FFO,
diluted
|
199,906
|
|
|
0.41
|
|
|
209,895
|
|
|
0.45
|
|
FFO as adjusted,
diluted
|
214,385
|
|
|
0.44
|
|
|
219,483
|
|
|
0.47
|
|
FAD,
diluted
|
196,551
|
|
|
|
|
190,103
|
|
|
|
NAREIT FFO, FFO as adjusted, FAD, and SPP Cash NOI are
supplemental non-GAAP financial measures that we believe are useful
in evaluating the operating performance of real estate investment
trusts (refer to the "Funds From Operations" and "Funds Available
for Distribution" sections of this release for additional
information). See "June 30, 2019 Discussion and Reconciliation
of Non-GAAP Financial Measures" for definitions, discussions of
their uses and inherent limitations, and reconciliations to the
most directly comparable financial measures calculated and
presented in accordance with GAAP on the Investor Relations section
of our website at http://ir.hcpi.com/financial-reconciliation.
SAME PROPERTY PORTFOLIO OPERATING SUMMARY
The table below outlines the year-over-year three month and
year-to-date SPP Cash NOI growth:
Year-Over-Year
Total SPP Cash NOI Growth
|
|
% of Total
SPP
|
Three
Month
|
Year-To-Date
|
Senior
housing
|
30.7%
|
1.4%
|
0.5%
|
Life
science
|
26.0%
|
6.1%
|
6.5%
|
Medical
office
|
37.1%
|
3.8%
|
4.2%
|
Other non-reportable
segments ("Other")
|
6.1%
|
2.5%
|
2.4%
|
Total
Portfolio
|
100.0%
|
3.5%
|
3.5%
|
|
|
|
|
|
|
|
RECENT TRANSACTION UPDATES
THE HARTWELL INNOVATION CAMPUS ACQUISITION
In July 2019, HCP acquired a
$228 million life science campus
known as The Hartwell Innovation Campus ("Hartwell") located in the
suburban Boston submarket of
Lexington, Massachusetts, which
represents a 5.25% year one cash capitalization rate. The 277,000
square feet campus, comprised of four buildings, is 100% leased to
seven biopharmaceutical and medical diagnostics tenants. The
Hartwell acquisition brings HCP's life science presence in
Boston to approximately one
million square feet (inclusive of the 75 Hayden development) and is
HCP's third campus owned in partnership with leading local partner
King Street Properties.
OAKMONT PORTFOLIO ACQUISITION
In July 2019, HCP acquired a
portfolio of five senior housing properties in California operated by Oakmont totaling 430
units for $284 million. The
properties are located in Huntington
Beach, Los Angeles,
San Jose and San Francisco. The average age of the
properties is less than two years. As part of the transaction, HCP
assumed $112 million of secured debt
and issued downREIT units at $32.05
per share for approximately 11% of the $284
million purchase price. The year one cash capitalization
rate is in the mid 5's.
HCP continues to expand its relationship with Oakmont,
demonstrating our commitment to grow with a top-tier operator and
developer in high barrier to entry California markets.
SAN DIEGO LIFE SCIENCE
ACQUISITION
In July 2019, HCP acquired a
$16 million, two-story office
building in the Sorrento Mesa submarket of San Diego. The 56,000 square foot property is
located on HCP's Directors Place campus which includes two existing
life science buildings and a future development site. HCP intends
to place the property into redevelopment in 2020 upon the
expiration of the in-place leases and convert the building from
office to lab. This value-add acquisition has an expected yield of
8% upon stabilization.
OVERLAND PARK
ACQUISITION
In May 2019, HCP acquired a
medical office building in Overland
Park, an affluent suburb of Kansas
City. The purchase price was $15
million, which represents a 5.5% year one cash
capitalization rate. The 38,000 square foot property is 100% leased
and is located on campus of HCA's Midwest Menorah Medical Center, a
154-bed acute care leading local hospital. This acquisition
augments our local footprint, as we already own an existing 59,000
square foot medical office building on the same campus.
PRIME CARE DISPOSITION
HCP entered into a definitive agreement to sell our direct
financing lease interests in 13 non-core senior housing properties
to Prime Care, LLC and its affiliates ("Prime Care") for
$274 million. The properties are
currently leased to Prime Care under direct financing leases and
were acquired by HCP as part of the CNL transaction in 2006. The
properties are managed by Sunrise (11) and Harbor Retirement
Associates ("HRA") (2). The direct financing leases have bargain
purchase options at lease maturity.
The disposition of these properties is consistent with HCP's
strategy of eliminating complex financing arrangements that do not
align incentives among the parties, and recycling capital into
newer properties. The transaction has a yield on sale of 8.2% and
is expected to close in the third quarter of 2019.
AEGIS LEASE RENEWAL
HCP renewed the 10-property senior housing master lease with
Aegis for an additional 10 years. The master lease now matures in
July 2030. These are high-quality,
high-performing properties in Seattle and California with strong coverage.
HRA LEASE AMENDMENT
In the second quarter, HCP entered into an agreement with HRA to
amend the existing leases. HCP will sell six low performing non
core properties and combine the remaining 8 properties into a
single master lease with a common maturity date in December 2028 and 2.5% annual escalators. HCP
received improved lease covenants and guaranties, and will fund up
to $10 million of capital
improvements which will generate a yield of 6.5%. The restructuring
also improves the geographic footprint and asset quality of HCP's
HRA portfolio.
DEVELOPMENT UPDATES
MEDICAL OFFICE DEVELOPMENT PROGRAM WITH HCA
In July 2019, HCP signed a
definitive agreement on a $12
million, 42,000 square foot, on-campus medical office
development, located in Brooksville,
Florida (Tampa MSA). The project consists of a two-story
medical office building located on HCA's Oak Hill Hospital campus.
HCA has committed to lease 55% of the space.
HCP's development program with HCA now includes five development
projects, with a total estimated development spend of approximately
$110 million.
THE COVE PHASE III DELIVERY
In the second quarter of 2019, HCP completed and delivered Phase
III of The Cove, which consists of 324,000 square feet of Class A
life science space. The two completed buildings are part of HCP's
best-in-class, one million square foot life science campus in
South San Francisco and are 100%
occupied by a strong roster of tenants generating a stabilized
yield of approximately 9.5%. The completion of this development
project further solidifies our position as the dominant life
science landlord in South San
Francisco.
PREVIOUSLY ANNOUNCED TRANSACTION UPDATES
SIERRA POINT TOWERS ACQUISITION
During the second quarter of 2019, HCP completed the previously
announced acquisition of Sierra Point Towers, a 427,000 square
foot, two-building life science and office campus in the
South San Francisco life science
submarket for $245 million.
Sierra Point Towers is strategically
located adjacent to our The Shore at Sierra Point development
project and together creates a Class A life science campus with
over one million square feet.
DISCOVERY PORTFOLIO ACQUISITION
In April 2019, HCP closed on the
previously announced acquisition of nine newly-built senior housing
properties operated by Discovery for $445
million. The properties are located in the high-growth
markets of Florida (7),
Georgia (1) and Texas (1).
OAKMONT PORTFOLIO ACQUISITION
In May 2019, HCP closed on the
previously announced acquisition of three newly-built senior
housing properties operated by Oakmont and located in California (Los
Angeles, Bay Area, and
Sacramento) for $113 million.
SUNRISE RIDEA CONVERSIONS
In the second quarter of 2019, HCP completed the previously
announced conversion of 15 high quality senior housing properties
operated by Sunrise from triple-net leases to RIDEA structures.
This is in addition to the 18 Sunrise senior housing properties
converted to RIDEA in the prior quarter. HCP remains on track to
convert two additional Sunrise triple-net lease properties to RIDEA
structures in the second half of 2019. Sunrise will remain the
operator of all 35 properties.
BALANCE SHEET AND CAPITAL MARKET ACTIVITIES
SENIOR UNSECURED NOTES
In July 2019, HCP completed a
public offering of senior unsecured notes for total gross proceeds
of $1.3 billion across two tranches:
$650 million of 3.250% notes due 2026
and $650 million of 3.500% notes due
2029.
Net proceeds from the offering were used to (i) redeem all of
HCP's outstanding $800 million 2.625%
senior unsecured notes due February
2020 and (ii) repurchase $250
million of HCP's 4.000% senior unsecured notes due 2022 and
$250 million of HCP's 4.250% senior
unsecured notes due 2023, pursuant to tender offers completed in
July 2019.
In connection with the foregoing redemption and tender offers,
HCP incurred a loss on debt extinguishment of approximately
$35 million in July 2019.
REVOLVING CREDIT FACILITY AND NEW TERM LOAN
In May 2019, HCP closed on a
$2.5 billion unsecured revolving
credit facility ("credit facility") and a new five year
$250 million unsecured term
loan. HCP successfully reduced its borrowing costs by 5 basis
points under the credit facility and extended the maturity date to
May 23, 2023, plus two six-month
extension options at HCP's discretion. Based on HCP's current
senior unsecured long-term debt ratings, the credit facility bears
interest annually at LIBOR plus 82.5 basis points with a facility
fee of 15 basis points, and the term loan bears interest annually
at LIBOR plus 90 basis points.
At June 30, 2019, HCP had
$2 billion available under its credit
facility.
EQUITY CAPITAL MARKETS ACTIVITY
From May through July 2019, we
sold 15.7 million shares of common stock under our ATM program at
an initial weighted average net price of $31.53 per share.
- 9.8 million shares of common stock were sold via forward sales
agreements
- 5.9 million shares of common stock were sold directly for net
proceeds of $189 million
As of July 3, 2019, HCP had
settled seven million shares that were sold under forward sales
agreements for net proceeds of $213
million, and 23 million shares remained outstanding under
forward contracts. We expect to settle the remaining forward
contracts within the next 12 months to fund acquisition,
development and other investment activities.
DIVIDEND
On July 25, 2019, we announced
that our Board declared a quarterly cash dividend of $0.37 per common share. The dividend will be paid
on August 20, 2019, to stockholders
of record as of the market close on August
5, 2019.
SUSTAINABILITY
In May 2019, HCP was named to
Corporate Responsibility (CR) Magazine's 100 Best Corporate
Citizens List for 2019. The roster recognizes the standout
environmental, social and governance ("ESG") performance of public
companies across the United
States. Furthermore, for the first time, we were named as a
constituent in the Dow Jones Global 1200 ESG Index. More
information about HCP's sustainability efforts, including a link to
our Sustainability Report, is available on our website at
www.hcpi.com/sustainability.
2019 GUIDANCE
For full year 2019, we are updating the following guidance
ranges:
- Diluted net income per share to range between $0.15 to $0.21
- Diluted NAREIT FFO per share of $1.62 to $1.66
- Diluted FFO as adjusted per share of $1.73 to $1.77
- Blended Total Portfolio SPP Cash NOI growth of 2% to 3%
These estimates do not reflect the potential impact from
unannounced future transactions other than capital recycling
activities. For additional details and information regarding these
estimates, refer to the 2019 Guidance section of our corresponding
Supplemental Report and the Discussion and Reconciliation of
Non-GAAP Financial Measures, which are both available in the
Investor Relations section of our website
at http://ir.hcpi.com.
COMPANY INFORMATION
HCP has scheduled a conference call and webcast for Thursday, August 1, 2019, at 9:00 a.m.
Pacific Time (12:00 p.m. Eastern Time) to present its
performance and operating results for the second quarter ended
June 30, 2019. The conference
call is accessible by dialing (888) 317-6003 (U.S.) or (412)
317-6061 (International). The conference ID number is 4351219. You
may also access the conference call via webcast in the Investor
Relations section of our website at http://ir.hcpi.com. An archive
of the webcast will be available on HCP's website through
August 1, 2020, and a telephonic
replay can be accessed through August 16,
2019, by dialing (877) 344-7529 (U.S.) or (412) 317-0088
(International) and entering conference ID number 10132487. Our
Supplemental Report for the current period is also available, with
this earnings release, in the Investor Relations section of our
website.
ABOUT HCP
HCP, Inc. is a fully integrated real estate investment trust
(REIT) that invests in real estate serving the healthcare industry
in the United States. HCP
owns a large-scale portfolio primarily diversified across life
science, medical office and senior housing. Recognized as a global
leader in sustainability, HCP has been a publicly-traded company
since 1985 and was the first healthcare REIT selected to the
S&P 500 index. For more information regarding HCP,
visit www.hcpi.com.
FORWARD-LOOKING STATEMENTS
Statements in this release that are not historical facts are
"forward-looking statements" within the meaning of Section 27A
of the Securities Act of 1933, as amended, and Section 21E of
the Securities Exchange Act of 1934, as amended.
Forward-looking statements include, among other things, statements
regarding our and our officers' intent, belief or expectation as
identified by the use of words such as "may," "will," "project,"
"expect," "believe," "intend," "anticipate," "seek," "target,"
"forecast," "plan," "potential," "estimate," "could," "would,"
"should" and other comparable and derivative terms or the negatives
thereof. Examples of forward-looking statements include,
among other things: (i) statements regarding timing, outcomes
and other details relating to current, pending or contemplated
acquisitions, dispositions, transitions, developments,
redevelopments, joint venture transactions, capital recycling
plans, financing activities, or other transactions discussed in
this release, including without limitation those described under
the headings "Recent Transaction Updates," "Development Updates,"
"Previously Announced Transaction Updates" and "Balance Sheet and
Capital Markets Activities"; (ii) statements regarding the
payment of a quarterly cash dividend; and (iii) all statements
under the heading "2019 Guidance," including without limitation
with respect to expected net income, NAREIT FFO per share, FFO as
adjusted per share, SPP Cash NOI growth and other financial
projections and assumptions, as well as comparable statements
included in other sections of this
release. Forward-looking statements reflect our current
expectations and views about future events and are subject to risks
and uncertainties that could significantly affect our future
financial condition and results of operations. While
forward-looking statements reflect our good faith belief and
assumptions we believe to be reasonable based upon current
information, we can give no assurance that our expectations or
forecasts will be attained. Further, we cannot guarantee the
accuracy of any such forward-looking statement contained in this
release, and such forward-looking statements are subject to known
and unknown risks and uncertainties that are difficult to
predict. These risks and uncertainties include, but are not
limited to: our reliance on a concentration of a small number of
tenants and operators for a significant percentage of our revenues
and net operating income; the financial condition of our existing
and future tenants, operators and borrowers, including potential
bankruptcies and downturns in their businesses, and their legal and
regulatory proceedings, which results in uncertainties regarding
our ability to continue to realize the full benefit of such
tenants' and operators' leases and borrowers' loans; the ability of
our existing and future tenants, operators and borrowers to conduct
their respective businesses in a manner sufficient to maintain or
increase their revenues and manage their expenses in order to
generate sufficient income to make rent and loan payments to us and
our ability to recover investments made, if applicable, in their
operations; our concentration in the healthcare property sector,
particularly in senior housing, life sciences and medical office
buildings, which makes our profitability more vulnerable to a
downturn in a specific sector than if we were investing in multiple
industries; operational risks associated with third party
management contracts, including the additional regulation and
liabilities of our RIDEA lease structures; the effect on us and our
tenants and operators of legislation, executive orders and other
legal requirements, including compliance with the Americans with
Disabilities Act, fire, safety and health regulations,
environmental laws, the Affordable Care Act, licensure,
certification and inspection requirements, and laws addressing
entitlement programs and related services, including Medicare and
Medicaid, which may result in future reductions in reimbursements
or fines for noncompliance; our ability to identify replacement
tenants and operators and the potential renovation costs and
regulatory approvals associated therewith; the risks associated
with property development and redevelopment, including costs above
original estimates, project delays and lower occupancy rates and
rents than expected; the potential impact of uninsured or
underinsured losses; the risks associated with our investments in
joint ventures and unconsolidated entities, including our lack of
sole decision making authority and our reliance on our partners'
financial condition and continued cooperation; competition for the
acquisition and financing of suitable healthcare properties as well
as competition for tenants and operators, including with respect to
new leases and mortgages and the renewal or rollover of existing
leases; our or our counterparties' ability to fulfill obligations,
such as financing conditions and/or regulatory approval
requirements, required to successfully consummate acquisitions,
dispositions, transitions, developments, redevelopments, joint
venture transactions or other transactions; our ability to achieve
the benefits of acquisitions or other investments within expected
time frames or at all, or within expected cost projections; the
potential impact on us and our tenants, operators and borrowers
from current and future litigation matters, including the
possibility of larger than expected litigation costs, adverse
results and related developments; changes in federal, state or
local laws and regulations, including those affecting the
healthcare industry that affect our costs of compliance or increase
the costs, or otherwise affect the operations, of our tenants and
operators; our ability to foreclose on collateral securing our real
estate-related loans; volatility or uncertainty in the capital
markets, the availability and cost of capital as impacted by
interest rates, changes in our credit ratings, the value of our
common stock, and other conditions that may adversely impact our
ability to fund our obligations or consummate transactions, or
reduce the earnings from potential transactions; changes in global,
national and local economic and other conditions, including
currency exchange rates; our ability to manage our indebtedness
level and changes in the terms of such indebtedness; competition
for skilled management and other key personnel; our reliance
on information technology systems and the potential impact of
system failures, disruptions or breaches; our ability to maintain
our qualification as a real estate investment trust; and other
risks and uncertainties described from time to time in our
Securities and Exchange Commission filings. Except as
required by law, we do not undertake, and hereby disclaim, any
obligation to update any forward-looking statements, which speak
only as of the date on which they are made.
CONTACT
Andrew Johns
Vice President – Finance and Investor Relations
949-407-0400
HCP, Inc.
|
Consolidated
Balance Sheets
|
In thousands,
except share and per share data
|
(unaudited)
|
|
|
|
June 30,
2019
|
|
December 31,
2018
|
|
Assets
|
|
|
|
|
Real
estate:
|
|
|
|
|
Buildings and
improvements
|
$
|
11,784,671
|
|
|
$
|
10,877,248
|
|
|
Development costs and
construction in progress
|
496,662
|
|
|
537,643
|
|
|
Land
|
1,879,227
|
|
|
1,637,506
|
|
|
Accumulated
depreciation and amortization
|
(2,926,656)
|
|
|
(2,842,947)
|
|
|
Net real
estate
|
11,233,904
|
|
|
10,209,450
|
|
|
Net investment in
direct financing leases
|
357,104
|
|
|
713,818
|
|
|
Loans receivable,
net
|
124,559
|
|
|
62,998
|
|
|
Investments in and
advances to unconsolidated joint ventures
|
518,033
|
|
|
540,088
|
|
|
Accounts receivable,
net of allowance of $6,899 and $5,127
|
53,840
|
|
|
48,171
|
|
|
Cash and cash
equivalents
|
130,521
|
|
|
110,790
|
|
|
Restricted
cash
|
25,531
|
|
|
29,056
|
|
|
Intangible assets,
net
|
317,960
|
|
|
305,079
|
|
|
Assets held for sale,
net
|
160,999
|
|
|
108,086
|
|
|
Right-of-use asset,
net
|
172,424
|
|
|
—
|
|
|
Other assets,
net
|
618,218
|
|
|
591,017
|
|
|
Total
assets
|
$
|
13,713,093
|
|
|
$
|
12,718,553
|
|
|
|
|
|
|
|
Liabilities and
Equity
|
|
|
|
|
Bank line of
credit
|
$
|
530,004
|
|
|
$
|
80,103
|
|
|
Term loan
|
248,821
|
|
|
—
|
|
|
Senior unsecured
notes
|
5,262,694
|
|
|
5,258,550
|
|
|
Mortgage
debt
|
161,829
|
|
|
138,470
|
|
|
Other debt
|
87,211
|
|
|
90,785
|
|
|
Intangible
liabilities, net
|
53,771
|
|
|
54,663
|
|
|
Liabilities of assets
held for sale, net
|
30,093
|
|
|
1,125
|
|
|
Lease
liability
|
154,877
|
|
|
—
|
|
|
Accounts payable and
accrued liabilities
|
371,235
|
|
|
391,583
|
|
|
Deferred
revenue
|
193,286
|
|
|
190,683
|
|
|
Total
liabilities
|
7,093,821
|
|
|
6,205,962
|
|
|
Commitments and
contingencies
|
|
|
|
|
Common stock, $1.00
par value: 750,000,000 shares authorized; 491,108,584 and
477,496,499 shares issued and outstanding
|
491,109
|
|
|
477,496
|
|
|
Additional paid-in
capital
|
8,801,037
|
|
|
8,398,847
|
|
|
Cumulative dividends
in excess of earnings
|
(3,233,283)
|
|
|
(2,927,196)
|
|
|
Accumulated other
comprehensive income (loss)
|
(4,459)
|
|
|
(4,708)
|
|
|
Total stockholders'
equity
|
6,054,404
|
|
|
5,944,439
|
|
|
|
|
|
|
|
Joint venture
partners
|
388,617
|
|
|
391,401
|
|
|
Non-managing member
unitholders
|
176,251
|
|
|
176,751
|
|
|
Total noncontrolling
interests
|
564,868
|
|
|
568,152
|
|
|
Total
equity
|
6,619,272
|
|
|
6,512,591
|
|
|
Total liabilities
and equity
|
$
|
13,713,093
|
|
|
$
|
12,718,553
|
|
|
HCP, Inc.
|
Consolidated
Statements of Operations
|
In thousands,
except per share data
|
(unaudited)
|
|
|
|
Three Months
Ended
June 30,
|
|
Six Months Ended
June 30,
|
|
|
2019
|
|
2018
|
|
2019
|
|
2018
|
|
|
(unaudited)
|
|
|
|
|
|
Revenues:
|
|
|
|
|
|
|
|
|
Rental and related
revenues
|
$
|
301,197
|
|
|
$
|
317,840
|
|
|
$
|
595,419
|
|
|
$
|
634,592
|
|
|
Resident fees and
services
|
177,766
|
|
|
136,774
|
|
|
304,461
|
|
|
279,588
|
|
|
Income from direct
financing leases
|
10,190
|
|
|
13,490
|
|
|
23,714
|
|
|
26,756
|
|
|
Interest
income
|
2,414
|
|
|
1,447
|
|
|
4,127
|
|
|
7,812
|
|
|
Total
revenues
|
491,567
|
|
|
469,551
|
|
|
927,721
|
|
|
948,748
|
|
|
|
|
|
|
|
|
|
|
|
Costs and
expenses:
|
|
|
|
|
|
|
|
|
Interest
expense
|
56,942
|
|
|
73,038
|
|
|
106,269
|
|
|
148,140
|
|
|
Depreciation and
amortization
|
165,296
|
|
|
143,292
|
|
|
297,247
|
|
|
286,542
|
|
|
Operating
|
213,993
|
|
|
173,866
|
|
|
382,920
|
|
|
346,418
|
|
|
General and
administrative
|
27,120
|
|
|
22,514
|
|
|
48,475
|
|
|
51,689
|
|
|
Transaction
costs
|
1,337
|
|
|
2,404
|
|
|
5,855
|
|
|
4,599
|
|
|
Impairments
(recoveries), net
|
68,538
|
|
|
13,912
|
|
|
77,396
|
|
|
13,912
|
|
|
Total costs and
expenses
|
533,226
|
|
|
429,026
|
|
|
918,162
|
|
|
851,300
|
|
|
Other income
(expense):
|
|
|
|
|
|
|
|
|
Gain (loss) on sales
of real estate, net
|
11,448
|
|
|
46,064
|
|
|
19,492
|
|
|
66,879
|
|
|
Loss on debt
extinguishments
|
(1,135)
|
|
|
—
|
|
|
(1,135)
|
|
|
—
|
|
|
Other income
(expense), net
|
21,008
|
|
|
1,786
|
|
|
24,141
|
|
|
(38,621)
|
|
|
Total other income
(expense), net
|
31,321
|
|
|
47,850
|
|
|
42,498
|
|
|
28,258
|
|
|
Income (loss)
before income taxes and equity income (loss) from unconsolidated
joint ventures
|
(10,338)
|
|
|
88,375
|
|
|
52,057
|
|
|
125,706
|
|
|
Income tax benefit
(expense)
|
1,864
|
|
|
4,654
|
|
|
5,322
|
|
|
9,990
|
|
|
Equity income (loss)
from unconsolidated joint ventures
|
(1,506)
|
|
|
(101)
|
|
|
(2,369)
|
|
|
469
|
|
|
Net income
(loss)
|
(9,980)
|
|
|
92,928
|
|
|
55,010
|
|
|
136,165
|
|
|
Noncontrolling
interests' share in earnings
|
(3,617)
|
|
|
(2,986)
|
|
|
(7,137)
|
|
|
(5,991)
|
|
|
Net income (loss)
attributable to HCP, Inc.
|
(13,597)
|
|
|
89,942
|
|
|
47,873
|
|
|
130,174
|
|
|
Participating
securities' share in earnings
|
(394)
|
|
|
(461)
|
|
|
(837)
|
|
|
(852)
|
|
|
Net income (loss)
applicable to common shares
|
$
|
(13,991)
|
|
|
$
|
89,481
|
|
|
$
|
47,036
|
|
|
$
|
129,322
|
|
|
Earnings per
common share:
|
|
|
|
|
|
|
|
|
Basic
|
$
|
(0.03)
|
|
|
$
|
0.19
|
|
|
$
|
0.10
|
|
|
$
|
0.28
|
|
|
Diluted
|
$
|
(0.03)
|
|
|
$
|
0.19
|
|
|
$
|
0.10
|
|
|
$
|
0.28
|
|
|
Weighted average
shares outstanding:
|
|
|
|
|
|
|
|
|
Basic
|
478,739
|
|
|
469,769
|
|
|
478,260
|
|
|
469,664
|
|
|
Diluted
|
478,739
|
|
|
469,941
|
|
|
479,885
|
|
|
469,799
|
|
|
HCP, Inc.
|
Funds From
Operations
|
In
thousands, except per share data
|
(unaudited)
|
|
|
|
|
Three Months
Ended
June 30,
|
|
Six Months Ended
June 30,
|
|
|
|
2019
|
|
2018
|
|
2019
|
|
2018
|
|
Net income (loss)
applicable to common shares
|
|
$
|
(13,991)
|
|
|
$
|
89,481
|
|
|
$
|
47,036
|
|
|
$
|
129,322
|
|
|
Real estate related
depreciation and amortization
|
|
165,296
|
|
|
143,292
|
|
|
297,247
|
|
|
286,542
|
|
|
Real estate related
depreciation and amortization on unconsolidated joint
ventures
|
|
15,123
|
|
|
16,162
|
|
|
30,200
|
|
|
33,550
|
|
|
Real estate related
depreciation and amortization on noncontrolling interests and
other
|
|
(5,013)
|
|
|
(1,664)
|
|
|
(9,934)
|
|
|
(4,207)
|
|
|
Other real
estate-related depreciation and amortization
|
|
1,357
|
|
|
1,268
|
|
|
3,442
|
|
|
2,563
|
|
|
Loss (gain) on sales
of real estate, net
|
|
(11,448)
|
|
|
(46,064)
|
|
|
(19,492)
|
|
|
(66,879)
|
|
|
Loss (gain) on sales
of real estate, net on noncontrolling interests
|
|
208
|
|
|
—
|
|
|
208
|
|
|
—
|
|
|
Loss (gain) upon
consolidation of real estate, net(1)
|
|
(11,501)
|
|
|
—
|
|
|
(11,501)
|
|
|
41,017
|
|
|
Taxes associated with
real estate dispositions
|
|
—
|
|
|
1,147
|
|
|
—
|
|
|
1,147
|
|
|
Impairments
(recoveries) of depreciable real estate, net
|
|
58,391
|
|
|
6,273
|
|
|
67,249
|
|
|
6,273
|
|
|
NAREIT FFO applicable
to common shares
|
|
198,422
|
|
|
209,895
|
|
|
404,455
|
|
|
429,328
|
|
|
Distributions on
dilutive convertible units and other
|
|
1,484
|
|
|
—
|
|
|
3,279
|
|
|
—
|
|
|
Diluted NAREIT FFO
applicable to common shares
|
|
$
|
199,906
|
|
|
$
|
209,895
|
|
|
$
|
407,734
|
|
|
$
|
429,328
|
|
|
Diluted NAREIT FFO
per common share
|
|
$
|
0.41
|
|
|
$
|
0.45
|
|
|
$
|
0.84
|
|
|
$
|
0.91
|
|
|
Weighted average
shares outstanding - diluted NAREIT FFO
|
|
485,054
|
|
|
469,941
|
|
|
484,435
|
|
|
469,799
|
|
|
Impact of adjustments
to NAREIT FFO:
|
|
|
|
|
|
|
|
|
|
Transaction-related
items
|
|
$
|
6,435
|
|
|
$
|
1,993
|
|
|
$
|
12,324
|
|
|
$
|
3,934
|
|
|
Other impairments
(recoveries) and losses (gains), net(2)
|
|
10,147
|
|
|
7,639
|
|
|
10,147
|
|
|
4,341
|
|
|
Severance and related
charges(3)
|
|
3,728
|
|
|
—
|
|
|
3,728
|
|
|
8,738
|
|
|
Loss on debt
extinguishments
|
|
1,135
|
|
|
—
|
|
|
1,135
|
|
|
—
|
|
|
Litigation costs
(recoveries)
|
|
(527)
|
|
|
179
|
|
|
(399)
|
|
|
585
|
|
|
Casualty-related
charges (recoveries), net(4)
|
|
(6,242)
|
|
|
—
|
|
|
(6,242)
|
|
|
—
|
|
|
Foreign currency
remeasurement losses (gains)
|
|
(159)
|
|
|
(195)
|
|
|
(187)
|
|
|
(65)
|
|
|
Total
adjustments
|
|
14,517
|
|
|
9,616
|
|
|
20,506
|
|
|
17,533
|
|
|
FFO as adjusted
applicable to common shares
|
|
212,939
|
|
|
219,511
|
|
|
424,961
|
|
|
446,861
|
|
|
Distributions on
dilutive convertible units and other
|
|
1,446
|
|
|
(28)
|
|
|
3,226
|
|
|
(45)
|
|
|
Diluted FFO as
adjusted applicable to common shares
|
|
$
|
214,385
|
|
|
$
|
219,483
|
|
|
$
|
428,187
|
|
|
$
|
446,816
|
|
|
Diluted FFO as
adjusted per common share
|
|
$
|
0.44
|
|
|
$
|
0.47
|
|
|
$
|
0.88
|
|
|
$
|
0.95
|
|
|
Weighted average
shares outstanding - diluted FFO as adjusted
|
|
485,054
|
|
|
469,941
|
|
|
484,435
|
|
|
469,799
|
|
|
_______________________________________
|
(1)
|
For the three and six
months ended June 30, 2019, represents the gain related to the
acquisition of the outstanding equity interests in a previously
unconsolidated senior housing joint venture. For the six months
ended June 30, 2018, represents the loss on consolidation of seven
U.K. care homes.
|
(2)
|
For the three and six
months ended June 30, 2019, represents the impairment of 13 senior
housing triple-net facilities under DFLs recognized as a result of
entering into sales agreements. For the three months ended June 30,
2018, represents the impairment of an undeveloped life science land
parcel classified as held for sale. For the six months ended June
30, 2018, represents the impairment of an undeveloped life science
land parcel classified as held for sale, partially offset by an
impairment recovery upon the sale of our Tandem Mezzanine Loan in
March 2018.
|
(3)
|
For the three and six
months ended June 30, 2019, relates to the departure of certain
former employees. For the six months ended June 30, 2018, primarily
relates to the departure of our former Executive Chairman, which
consisted of $6 million of cash severance and $3 million of
equity award vestings.
|
(4)
|
For the three and six
months ended June 30, 2019, represents incremental insurance
proceeds received for property damage and other associated costs
related to hurricanes in 2017.
|
HCP, Inc.
|
|
Funds Available
for Distribution
|
|
In
thousands
|
|
(unaudited)
|
|
|
|
|
Three Months
Ended
June 30,
|
|
Six Months Ended
June 30,
|
|
|
2019
|
|
2018
|
|
2019
|
|
2018
|
|
FFO as adjusted
applicable to common shares
|
$
|
212,939
|
|
|
$
|
219,511
|
|
|
$
|
424,961
|
|
|
$
|
446,861
|
|
|
Amortization of
deferred compensation(1)
|
4,308
|
|
|
4,299
|
|
|
7,898
|
|
|
7,719
|
|
|
Amortization of
deferred financing costs
|
2,740
|
|
|
3,355
|
|
|
5,440
|
|
|
6,690
|
|
|
Straight-line
rents
|
(5,695)
|
|
|
(5,793)
|
|
|
(11,940)
|
|
|
(16,479)
|
|
|
FAD capital
expenditures
|
(19,513)
|
|
|
(26,346)
|
|
|
(38,733)
|
|
|
(45,592)
|
|
|
Lease restructure
payments
|
292
|
|
|
303
|
|
|
580
|
|
|
601
|
|
|
CCRC entrance
fees(2)
|
4,845
|
|
|
3,652
|
|
|
8,340
|
|
|
6,679
|
|
|
Deferred income
taxes
|
(3,897)
|
|
|
(5,731)
|
|
|
(7,629)
|
|
|
(7,871)
|
|
|
Other FAD
adjustments(3)
|
(952)
|
|
|
(3,147)
|
|
|
(2,381)
|
|
|
(6,774)
|
|
|
FAD applicable to
common shares
|
195,067
|
|
|
190,103
|
|
|
386,536
|
|
|
391,834
|
|
|
Distributions on
dilutive convertible units and other
|
1,484
|
|
|
—
|
|
|
3,278
|
|
|
—
|
|
|
Diluted FAD
applicable to common shares
|
$
|
196,551
|
|
|
$
|
190,103
|
|
|
$
|
389,814
|
|
|
$
|
391,834
|
|
|
Weighted average
shares outstanding - diluted FAD
|
485,054
|
|
|
469,941
|
|
|
484,435
|
|
|
469,799
|
|
|
_______________________________________
|
(1)
|
Excludes amounts
related to the acceleration of deferred compensation for restricted
stock units that vested upon the departure of certain former
employees, which have already been excluded from FFO as adjusted in
severance and related charges.
|
(2)
|
Represents our 49%
share of our CCRC JV's non-refundable entrance fees collected in
excess of amortization.
|
(3)
|
Primarily includes
our share of FAD capital expenditures from unconsolidated joint
ventures, partially offset by noncontrolling interests' share of
FAD capital expenditures from consolidated joint
ventures.
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/hcp-reports-second-quarter-2019-results-300894251.html
SOURCE HCP, Inc.